Progressive supranuclear palsy (PSP) is a rare brain disorder that causes serious and permanent problems with control of gait and balance. The most obvious sign of the disease is an inability to aim the eyes properly, which occurs because of lesions in the area of the brain that coordinates eye movements. Some patients describe this effect as a blurring. PSP patients often show alterations of mood and behavior, including depression and apathy as well as progressive mild dementia.
As the name suggests, the disease begins slowly and grows worse over time, causing weakness (palsy) by damaging certain parts of the brain above pea-sized structures (nuclei) that control eye movements (supranuclear).
Approximately 20,000 Americans - or one in every 100,000 people over the age of 60 - have PSP, making it much less common than Parkinson's disease, which affects more than 500,000 Americans. Patients are usually middle-aged or elderly, and men are affected more often than women.
PSP is caused by a gradual deterioration of brain cells in a few tiny but important places at the base of the brain, in the region called the brainstem. One of these areas, the substantia nigra, is also affected in Parkinson's disease, and damage to this region of the brain accounts for the motor symptoms that PSP and Parkinson's have in common.
Scientists do not know what causes these brain cells to degenerate but there are several theories about PSP's cause:
Initial complaints in PSP are typically vague and an early diagnosis is always difficult. The primary complaints fall into these categories:
PSP is often difficult to diagnose because its symptoms can be very much like those of other, more common movement disorders, and because some of the most characteristic symptoms may develop late or not at all. Some of its symptoms closely resemble those of Parkinson's disease, Alzheimer's disease, and rarer neurodegenerative disorders, such as Creutzfeldt-Jakob disease. The key to diagnosing PSP is identifying early gait instability and difficulty moving the eyes, the hallmark of the disease, as well as ruling out other similar disorders, some of which are treatable.
PSP gets progressively worse but is not itself directly life-threatening. It does, however, predispose patients to serious complications such as pneumonia secondary to difficulty in swallowing (dysphagia). The most common complications are choking and pneumonia, head injury, and fractures caused by falls. The most common cause of death is pneumonia. With good attention to medical and nutritional needs, it is possible for most PSP patients to live a decade or more after the first symptoms of the disease.
There is currently no effective treatment for PSP, although scientists are searching for better ways to manage the disease. In some patients the slowness, stiffness, and balance problems of PSP may respond to anti-parkinsonian agents such as levodopa, or levodopa combined with anticholinergic agents or amantadine, but the effect is usually temporary. The speech, vision, and swallowing difficulties usually do not respond to any drug treatment. Another group of drugs that has been of some modest success in PSP are antidepressant medications.
Non-drug treatment for PSP can take many forms. Patients frequently use weighted walking aids because of their tendency to fall backward. Bifocals or special glasses called prisms are sometimes prescribed for PSP patients to remedy the difficulty of looking down. Formal physical therapy is of no proven benefit in PSP, but certain exercises can be done to keep the joints limber. At some point, when swallowing disturbances make severe choking a definite risk, it may become necessary to perform a gastrostomy (or a jejunostomy), a minimally invasive surgical procedure. This surgery involves the placement of a tube through the skin of the abdomen into the stomach (intestine) for feeding purposes. Pallidotomy and other surgical procedures used in Parkinson's patients have not been proven effective in PSP.